Freenome Posts $60.1M Q3 Profit on $183.5M Revenue; $430M Cash Funds Runway Into 2028
FRNM is trading near its 52-week low of $9.71 (9.3% above the low).
Summary
Freenome's first 10-Q as a public company shows $183.5 million of Q3 revenue almost entirely from the Exact/Abbott FDA-approval milestone, a $60.1 million net profit flattered by one-time items, and $430.0 million of cash that management says lasts into 2028.
Key Events · Earnings and Guidance · FRNM
-
Q3 Revenue Jumps to $183.5M
Total revenue was $183.5 million versus $1.0 million a year ago, driven by $182.5 million of license and collaboration revenue under the Exact Sciences agreement.
-
Profit Is Milestone-Driven
Net income of $60.1 million ($0.60 basic, $0.58 diluted) included $157.5 million from the exclusive commercialization license and a $22.5 million cumulative catch-up after FDA approval of SimpleScreen CRC.
-
$430M Cash, Runway Into 2028
Cash, cash equivalents and short-term marketable securities totaled $430.0 million at September 30, 2026, which management says funds operations into 2028.
-
Both Convertible Notes Converted
Roche's $77.5 million converted into 6,460,616 shares at $12.00 at the July 20, 2026 closing; Exact's $50.5 million converted into 3,364,814 shares at $15.00 on September 8, 2026.
Analysis · FRNM · Industrial Applications And Services
The headline revenue was already out on November 10, but the full 10-Q shows the profit is largely accounting-driven: $182.5 million of the quarter's revenue came from recognizing the $100 million Exact/Abbott FDA-approval milestone plus a $22.5 million catch-up, and $41.9 million of stock compensation (including $39.7 million of RSU expense triggered by the SPAC closing) ran through operating expenses. What matters for the thesis is the balance sheet: $430.0 million of cash and securities after the $295.5 million de-SPAC/PIPE proceeds and the $100 million milestone received September 22, 2026, which management says funds operations into 2028. Both convertible notes are now gone — Roche's $77.5 million converted into 6,460,616 shares at $12.00 at closing and Exact's $50.5 million into 3,364,814 shares at $15.00 on September 8 — so the $11.6 million remeasurement loss is a non-cash mark-to-market on the Exact note before conversion, not new dilution or cash out. The real revenue engine (Abbott selling SimpleScreen CRC, royalties and future milestones) has not started contributing meaningfully yet.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, FRNM was trading at $10.61 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $9.71 to $17.50. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.